Safety Shot Announces Notice of Allowance for New Patent to Secure IP and Enforce Clinically Backed Claims
Safety Shot, Inc. (Nasdaq: SHOT) has announced a Notice of Allowance for a new U.S. patent covering its latest clinically-backed formula. This patent strengthens the company's portfolio of formulations designed to rapidly reduce blood alcohol content (BAC). Safety Shot's COO, David Sandler, highlighted this as a significant milestone in the company's mission to lead a new category addressing alcohol-related problems.
The patent supports Safety Shot's competitive advantage, including faster alcohol removal, improved cognitive ability, and reduced impairment. It also allows the company to enforce specific marketplace claims and solidifies its position as a leader in rapid alcohol reduction. CEO Jarret Boon emphasized the patent's role in supporting their industry-leading clinical findings and commitment to consumer solutions.
Safety Shot, Inc. (Nasdaq: SHOT) ha annunciato un Avviso di Concessione per un nuovo brevetto statunitense che copre la sua ultima formula supportata da evidenze cliniche. Questo brevetto rafforza il portafoglio di formulazioni dell'azienda, progettate per ridurre rapidamente il tasso alcolemico nel sangue (BAC). Il COO di Safety Shot, David Sandler, ha sottolineato questo come un traguardo significativo nella missione dell'azienda di guidare una nuova categoria che affronta i problemi legati all'alcol.
Il brevetto sostiene il vantaggio competitivo di Safety Shot, inclusa la rimozione più rapida dell'alcol, il miglioramento delle capacità cognitive e la riduzione dell'alterazione. Consente inoltre all'azienda di far valere specifiche affermazioni sul mercato e consolida la sua posizione di leader nella riduzione rapida dell'alcol. Il CEO Jarret Boon ha enfatizzato il ruolo del brevetto nel sostenere i loro risultati clinici di prima linea e l'impegno verso soluzioni per i consumatori.
Safety Shot, Inc. (Nasdaq: SHOT) ha anunciado un Aviso de Concesión para una nueva patente en EE. UU. que cubre su última fórmula respaldada clínicamente. Esta patente refuerza el portafolio de formulaciones de la empresa, diseñadas para reducir rápidamente el contenido de alcohol en sangre (BAC). El COO de Safety Shot, David Sandler, destacó esto como un hito significativo en la misión de la empresa de liderar una nueva categoría que aborde los problemas relacionados con el alcohol.
La patente respalda la ventaja competitiva de Safety Shot, que incluye la eliminación más rápida del alcohol, la mejora de la capacidad cognitiva y la reducción de la alteración. También permite a la empresa hacer valer afirmaciones específicas en el mercado y consolida su posición como líder en la reducción rápida de alcohol. El CEO Jarret Boon enfatizó el papel de la patente en el apoyo a sus hallazgos clínicos líderes en la industria y al compromiso con las soluciones para los consumidores.
세이프티 샷 주식회사 (Nasdaq: SHOT)는 최신 임상 지원 포뮬러를 다루는 미국 특허의 허가 통지를 발표했습니다. 이 특허는 혈중 알코올 농도(BAC)를 신속하게 감소시키기 위해 설계된 회사의 제형 포트폴리오를 강화합니다. 세이프티 샷의 COO인 데이비드 샌들러는 이를 알코올 관련 문제를 해결하는 새로운 카테고리를 선도하기 위한 회사의 미션에 있어 중요한 이정표로 강조했습니다.
이 특허는 세이프티 샷의 경쟁 우위를 지원하며, 신속한 알코올 제거, 향상된 인지 능력, 감소된 장애를 포함합니다. 또한 회사가 특정 시장 주장을 시행할 수 있도록 하며, 신속한 알코올 감소의 선두주자로서의 입지를 확고히 합니다. CEO인 자렛 분은 이 특허가 그들의 산업 최고의 임상 결과와 소비자 솔루션에 대한 헌신을 지원하는 역할을 한다고 강조했습니다.
Safety Shot, Inc. (Nasdaq: SHOT) a annoncé un Avis de Concession pour un nouveau brevet américain couvrant sa dernière formule soutenue par des études cliniques. Ce brevet renforce le portefeuille de formulations de l'entreprise, conçues pour réduire rapidement le taux d'alcool dans le sang (BAC). Le COO de Safety Shot, David Sandler, a souligné cela comme un jalon significatif dans la mission de l'entreprise de diriger une nouvelle catégorie s'attaquant aux problèmes liés à l'alcool.
Le brevet soutient l'avantage concurrentiel de Safety Shot, y compris une élimination plus rapide de l'alcool, une amélioration des capacités cognitives et une réduction de l'altération. Il permet également à l'entreprise de faire valoir des affirmations spécifiques sur le marché et consolide sa position en tant que leader dans la réduction rapide de l'alcool. Le CEO Jarret Boon a souligné le rôle du brevet dans le soutien de leurs résultats cliniques de premier plan et leur engagement envers des solutions pour les consommateurs.
Safety Shot, Inc. (Nasdaq: SHOT) hat eine Zulassungsmitteilung für ein neues US-Patent veröffentlicht, das ihre neueste klinisch unterstützte Formel abdeckt. Dieses Patent stärkt das Portfolio des Unternehmens für Formulierungen, die darauf abzielen, den Blutalkoholgehalt (BAC) schnell zu reduzieren. Der COO von Safety Shot, David Sandler, hob dies als wichtigen Meilenstein in der Mission des Unternehmens hervor, eine neue Kategorie zur Bekämpfung alkoholbedingter Probleme zu führen.
Das Patent unterstützt den Wettbewerbsvorteil von Safety Shot, einschließlich einer schnelleren Alkoholentfernung, verbessertem kognitiven Fähigkeiten und reduzierter Beeinträchtigung. Es ermöglicht dem Unternehmen auch, spezifische Marktansprüche durchzusetzen und festigt seine Position als Marktführer in der schnellen Alkoholreduktion. CEO Jarret Boon betonte die Rolle des Patents bei der Unterstützung ihrer branchenführenden klinischen Erkenntnisse und dem Engagement für Verbraucherlösungen.
- Received Notice of Allowance for a new U.S. patent covering latest formula
- Strengthens intellectual property portfolio in rapid alcohol reduction
- Supports claims of faster alcohol removal and improved cognitive ability
- Allows enforcement of specific marketplace claims
- Solidifies position as leader in rapid alcohol reduction category
- None.
Insights
The Notice of Allowance for Safety Shot's new patent is a significant development in the alcohol reduction market. This patent strengthens their intellectual property portfolio and supports their claims of rapidly reducing Blood Alcohol Content (BAC). The company's focus on clinical backing and patent protection sets a high bar for potential competitors.
From a medical perspective, the ability to lower BAC in as little as 30 minutes could have substantial implications for public health and safety. However, it's important to note that while this product may reduce BAC, it doesn't necessarily eliminate all effects of alcohol or guarantee sobriety. Further independent studies would be beneficial to validate the product's efficacy and safety profile.
The company's commitment to R&D and expanding their product formats is promising, but investors should closely monitor future clinical trials and regulatory approvals to fully assess the product's potential impact on alcohol-related health issues.
Safety Shot's patent allowance represents a strategic move to dominate the nascent 'rapid alcohol reducer' market. By securing intellectual property rights, the company is positioning itself as the pioneer in this new category, potentially creating significant barriers to entry for competitors.
The market potential for such a product could be substantial, considering the global prevalence of alcohol consumption and related issues. However, consumer adoption will depend on factors such as pricing, accessibility and public perception. Safety Shot's success will hinge on effective marketing strategies and educating consumers about the product's benefits and limitations.
Investors should watch for partnerships with bars, restaurants, or ride-sharing services, as these could significantly boost product visibility and sales. Additionally, keep an eye on regulatory responses and potential pushback from alcohol industry stakeholders.
The Notice of Allowance for Safety Shot's new patent is a crucial legal milestone. It not only protects their intellectual property but also provides a strong foundation for enforcing their claims against potential infringers. This legal protection is particularly valuable in a new and potentially lucrative market segment.
However, investors should be aware that patent protection doesn't guarantee market success. The company may face challenges in regulatory compliance, particularly with food and drug administrations worldwide. The product's claims of reducing BAC and improving cognitive ability post-alcohol consumption could attract scrutiny from regulatory bodies.
Furthermore, the company's assertive stance against "inferior products" suggests a readiness for potential legal battles. While this demonstrates confidence, it also implies a risk of future litigation costs. Monitoring the company's legal strategies and any challenges to their patents will be important for assessing long-term viability.
New Patent is Added to the Company’s Portfolio of Formulations that Rapidly Reduce Blood Alcohol Content
JUPITER, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or “the Company”), a wellness company behind the world's first rapid alcohol reducer that lowers blood alcohol content (“BAC”) by supporting its metabolism in as little as 30 minutes, has announced the Notice of Allowance of for a U.S. patent that covers its newest clinically-backed formula.
“This latest patent marks a significant milestone in Safety Shot’s quest to lead a brand-new category that the Company has created to solve alcohol related problems,” stated Safety Shot COO and co-owner of the patent, David Sandler.
The Company’s family of patents aims to corroborate Safety Shot’s competitive advantage in the market which includes being faster at removing alcohol, improving cognitive ability, and reducing impairment by supporting the metabolism of alcohol. The latest patent continues to advance an exciting new category of functionality.
“The patent locks up our IP and further separates us from the pack as the only the group that has been able prove that Safety’s Shot revolutionary formula can dramatically reduce blood alcohol and reduce the build-up toxins associated with alcohol consumption rapidly. This patent helps solidify Safety Shot as the uncontested world leader in making people feel better faster,” continued Sandler, who co-invented the Safety Shot wellness product.
“The patent allows Safety Shot to exercise authority over specific claims in the marketplace. It further proves our commitment to finding solutions for consumers while taking a hard stance against other companies that enter the category with inferior products. Our patents provide enforceable support to our industry-leading clinical findings,” noted Safety Shot CEO and patent co-owner, Jarret Boon.
As part of the Company’s efforts to be recognized as the world leader in combating the ill effects of alcohol, the team at Safety Shot is committed to advancing its science through its robust R&D platform that offers a variety of formats using its clinically proven, patented formula.
About Safety Shot, Inc.
Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot’s ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled “Risk Factors” in Safety Shot’s Form 10-Q for the fiscal year ended June 30, 2024, filed with the Securities and Exchange Commission on August 15, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.
Media and Investor Contact:
Autumn Communications
Jess Weinberger
Phone: 201-213-3239
Email: shot@autumncommunications.com
Investor Relations
Medon Michaelides
Phone: 561-244-7100
Email: investors@drinksafetyshot.com
FAQ
What is the latest patent announcement from Safety Shot (SHOT)?
How does the new patent benefit Safety Shot (SHOT)?
What are the key features of Safety Shot's (SHOT) alcohol reduction formula?
Who are the key figures mentioned in Safety Shot's (SHOT) patent announcement?
